You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Robust Predictor of Colon Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 102

    Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution

    SBC: SGgenomics, Inc.            Topic: 101

    PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury

    SBC: Lydex Pharmaceuticals LLC            Topic: 300

    Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted Chelation for Reversal of Vascular Calcification

    SBC: Elastrin Therapeutics Inc.            Topic: NHLBI

    PROJECT SUMMARY Medial arterial calcification is a form of vessel hardening in which calcium deposits are found in the medial layer of elastic and muscular arteriesspecifically on elastic fibersleading to arterial stiffening and tearingAn independent risk factor for cardiovascular diseases in diabetic and chronic kidney disease patientsit predisposes the patients to cardiovascular mortality and lo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government